MDCXW Medicus Pharma Ltd. - Warrant
NASDAQ · View on SEC EDGAR ↗ close Sep 22, 2026 10-K/10-Q Aug 12, 2026
$0.30
· of 52w range
· above low
· to high
$0.3052w low
$2.5052w high
Market Cap (MRQ)
$18M
P/E
-0.9
EPS
$-2.74
your badges
52W Range
$0–$2
Analyst Rating
·
Price Target
·
P/E
-0.9
ROE
·
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
MDCXW Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$0.30
Market Cap (MRQ)
$18M
P/E
-0.9
EPS
$-2.74
52W Range
$0–$3
MDCXW Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
EPS$-2.742023-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | MDCXW | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -0.9 | · | · | · | |
| P/B (MRQ) | -10.2 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | MDCXW | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 1.6 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| R&D Expense | $8M | $4M | $193.6K | |
| SG&A Expense | $18M | $8M | $5M | |
| Operating Expenses | $34M | $11M | $5M | |
| Operating Income | $-34M | $-11M | $-5M | |
| Other Non-op | $-1M | $25.4K | $-584.8K | |
| Income Tax | $0 | $0 | $0 | |
| Net Income | $-47M | $-11M | $-5M | |
| EPS (Basic) | $-2.74 | $-1.16 | $-1.53 | |
| EPS (Diluted) | $-2.74 | $-1.16 | $-1.53 | |
| Shares (Basic) | 17,283,824 | 9,619,184 | 3,479,494 | |
| Shares (Diluted) | 17,283,824 | 9,619,184 | 3,479,494 |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & Equivalents | $9M | $4M | $2M | |
| Prepaid Expense | $1M | $1M | $173.7K | |
| Current Assets | $10M | $5M | $2M | |
| Total Assets | $10M | $6M | $2M | |
| Accounts Payable | $3M | $1M | $210.8K | |
| Current Liabilities | $10M | $2M | $781.6K | |
| Capital Leases | $60.1K | $205.9K | $0 | |
| Total Liabilities | $10M | $3M | $781.6K | |
| Common Stock | $57M | $31M | $19M | |
| Paid-in Capital | $7M | $2M | $98.6K | |
| Retained Earnings | $-64M | $-29M | $-18M | |
| AOCI | $10.9K | $0 | · | |
| Stockholders' Equity | $-67.6K | $3M | $1M | |
| Liabilities + Equity | $10M | $6M | $2M | |
| Shares Outstanding | 25,176,303 | 11,816,721 | 8,076,673 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Stock-based Comp | $2M | $713.1K | $98.6K | |
| Deferred Tax | $0 | $0 | · | |
| Operating Cash Flow | $-23M | $-10M | $-4M | |
| Investing Cash Flow | $-5M | $0 | · | |
| Stock Issued | $10M | $5M | $0 | |
| Financing Cash Flow | $32M | $13M | $6M | |
| Net Change in Cash | $5M | $2M | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| EPS (TTM) | $-2.74 | $-1.16 | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue TTM | $-197.4K | $25.4K | · | |
| Net Income TTM | $-47M | $-11M | · | |
| P/E | -0.9 | · | · | |
| Earnings Yield | -109.6% | · | · |
Income Statement
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $5M | $3M | $2M | $1M | $2M | $1M | $564.1K | $1M | $321.4K | |
| SG&A Expense | $7M | $10M | $5 | $5M | $3M | $2M | $2M | $2M | $1M | |
| Operating Expenses | $11M | $23M | $15 | $6M | $5M | $4M | $2M | $4M | $2M | |
| Operating Income | $-11M | $-23M | $-15 | $-6M | $-5M | $-4M | $-2M | $-4M | $-2M | |
| Interest Expense | $205.6K | · | · | $0 | · | · | · | · | · | |
| Other Non-op | $-205.6K | $-394.0K | $-555.0K | $-160.0K | $23.9K | $48.9K | $55.5K | $-79.0K | $0 | |
| Net Income | $-12M | $-15M | $-21M | $-6M | $-5M | $-4M | $-2M | $-4M | $-2M | |
| EPS (Basic) | $-0.21 | $-0.77 | $-1.12 | $-0.43 | $-0.42 | $-0.27 | $-0.24 | $-0.44 | $-0.21 | |
| EPS (Diluted) | $-0.21 | $-0.77 | $-1.12 | $-0.43 | $-0.42 | $-0.27 | $-0.24 | $-0.44 | $-0.21 | |
| Shares (Basic) | 55,055,225 | · | 18,631,668 | 14,284,261 | 12,240,437 | · | 9,514,738 | 8,167,993 | 8,076,673 | |
| Shares (Diluted) | 55,055,225 | · | 18,631,668 | 14,284,261 | 12,240,437 | · | 9,514,738 | 8,167,993 | 8,076,673 | |
| EBITDA | $-11M | · | $-15 | $-6M | $-5M | · | · | · | · |
Balance Sheet
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $9M | $9M | $10M | $4M | $4M | · | · | · | |
| Prepaid Expense | $2M | $1M | $1M | $1M | $1M | $1M | · | · | · | |
| Current Assets | $17M | $10M | $10M | $11M | $5M | $5M | · | · | · | |
| Total Assets | $27M | $10M | $10M | $12M | $6M | $6M | · | · | · | |
| Accounts Payable | $7M | $3M | $2M | $2M | $2M | $1M | · | · | · | |
| Current Liabilities | $11M | $10M | $11M | $9M | $3M | $2M | · | · | · | |
| Capital Leases | $0 | $60.1K | $95.2K | $141.8K | $174.4K | $205.9K | · | · | · | |
| Total Liabilities | $29M | $10M | $11M | $9M | $4M | $3M | · | · | · | |
| Common Stock | $74M | $57M | $4 | $38M | $33M | $31M | · | · | · | |
| Paid-in Capital | $9M | $7M | $6M | $6M | $3M | $2M | · | · | · | |
| Retained Earnings | $-85M | $-64M | $-5 | $-40M | $-34M | $-29M | · | · | · | |
| AOCI | $61.1K | $10.9K | $10.7K | · | · | $0 | · | · | · | |
| Stockholders' Equity | $-2M | $-67.6K | $-910.1K | $3M | $2M | $3M | · | · | · | |
| Liabilities + Equity | $27M | $10M | $10M | $12M | $6M | $6M | · | · | · | |
| Shares Outstanding | 60,168,044 | 25,176,303 | 20,971,122 | 15,936,266 | 13,417,561 | 11,816,721 | · | · | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $429.7K | $852.8K | $117.4K | $112.3K | $91.7K | $0 | $585.4K | $36.0K | |
| Operating Cash Flow | $-7M | $-7M | $-7M | $-5M | $-4M | $-3M | $-3M | $-3M | $-1M | |
| Investing Cash Flow | · | $0 | · | · | · | $0 | · | · | · | |
| Stock Issued | $0 | $0 | $0 | $6M | · | $0 | · | · | · | |
| Financing Cash Flow | $26M | $7M | $10M | $11M | $4M | $2M | $0 | $11M | $0 | |
| Net Change in Cash | $19M | $43.1K | $-1M | $6M | · | $-1M | · | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | -0.13% | -15038.7% | · | · | · | · | · | |
| Net Margin | · | · | -180917.3% | · | · | · | · | · | · | |
| EBITDA Margin | · | · | -0.13% | -15038.7% | · | · | · | · | · | |
| ROA | -59.5% | · | -419.7% | · | -180.4% | · | · | · | · | |
| ROE | -1564.6% | · | 4600.6% | · | -475.2% | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | · | 0.9 | 1.3 | 1.5 | · | · | · | · | |
| Quick Ratio | 1.4 | · | 0.8 | 1.1 | 1.2 | · | · | · | · | |
| Interest Coverage | -55.8 | · | · | · | · | · | · | · | · |
Efficiency
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | · | · | · | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.03 | · | $-0.04 | $0.20 | $0.16 | · | · | · | · | |
| Revenue / Share | · | · | $0.00 | $0.00 | · | · | · | · | · | |
| Cash Flow / Share | · | · | · | · | $-0.32 | · | · | · | · | |
| Cash / Share | $0.25 | · | $0.41 | $0.61 | $0.30 | · | · | · | · | |
| EPS (TTM) | $-2.41 | · | $-2.24 | $-1.36 | $-1.37 | · | · | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-57M | · | $-36M | $-17M | $-15M | · | · | · | · | |
| Market Cap | $41M | · | $52M | $40M | · | · | · | · | · | |
| P/E | -0.3 | · | -1.1 | -1.8 | · | · | · | · | · | |
| P/B | -23.2 | · | -57.6 | 12.3 | · | · | · | · | · | |
| P / Tangible Book | · | · | · | 12.3 | · | · | · | · | · | |
| Earnings Yield | -354.7% | · | -89.6% | -54.4% | · | · | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net Income | $-47M | $-11M | $-5M |
| Diluted EPS | $-2.74 | $-1.16 | $-1.53 |
No data for this statement
Not enough fundamentals data to build this statement yet.
No data for this statement
Not enough fundamentals data to build this statement yet.
Institutional owners (13F) 4 filers · $64K total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
4
Value held
$64K
New positions
0
Exited positions
2
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 0 (-1 vs prior Q) | 2 (+2 vs prior Q) | 1 (+1 vs prior Q) | 0 (0 vs prior Q) | -60K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | $39,390 | 60,600 | 61.89% | Shares |
| Anson Funds Management LP | $18,923 | 42,400 | 29.73% | Shares |
| Connective Capital Management, LLC | $3,900 | 6,000 | 6.13% | Shares |
| UBS Group AG | $1,432 | 2,203 | 2.25% | Shares |
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| BOKHARI, RAZA, RBx Capital, LP | Sept. 14, 2026 | 5.30% | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 5 insiders · 5 officers · 1 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Raza Bokhari | Chief Executive Officer | Sept. 4, 2026 A | 2,941,176 | 0 | 0 | $0 |
| Carolyn F. Bonner | President and CFO | Sept. 4, 2026 A | 1,489,493 | 0 | 0 | $0 |
| Andrew Alasdair Smith | Chief Operating Officer | Sept. 4, 2026 A | 735,458 | 0 | 0 | $0 |
| Edward J. Brennan | Chief Scientific Officer | Sept. 4, 2026 A | 674,735 | 0 | 0 | $0 |
| Faisal Mehmud | Chief Medical Officer | Sept. 4, 2026 A | 1,470,588 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 12, 2026